Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Lymphoma 2Leukemia 2Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Cyclophosphamide 217fludarabine phosphate 120Rituximab 108Filgrastim 100Peripheral Blood Stem Cell Transplantation 86Etoposide 83fludarabine 80Busulfan 80Radiotherapy 76Tacrolimus 73Methotrexate 73Melphalan 71Mycophenolic Acid 70Cytarabine 65Antilymphocyte Serum 61Whole-Body Irradiation 56Cyclosporine 54Vincristine 49Prednisone 42Doxorubicin 41Methylprednisolone 34Granulocyte Colony-Stimulating Factor 34Dexamethasone 30Cord Blood Stem Cell Transplantation 29sargramostim 27Alemtuzumab 26Stem Cell Transplantation 24Carmustine 24Thiotepa 23thymoglobulin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × siplizumab × Other hematologic neoplasm × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

NCT00105313 2007-06-14

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

MedImmune LLC

Phase 1 Terminated
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡